In Vivo Safety
Standard and custom-built in vivo studies to help you identify potential safety liabilities early and de-risk your potential drug candidates.
)
Assessing potential safety liability early
Essential to optimizing drug design and progression into non-clinical development is assessment of safety with understanding of therapeutic related aspects such as DMPK. This requires timely and integrated approaches to understand and, as needed, address potential inherent target or compound related issues.
Creating a solid foundation to enable further development
In early discovery, where decisions need to be made quickly to enable rapid progress, often on limited budgets, quality data that can be relied on is key to create the foundation for success. Working with a partner that can help you by doing the right study to answer the right question is key.
Innovative modalities need innovative approaches
Whether your therapeutic is a based on an established large or small molecule platform, is a complex medicine, or an advanced therapy technology; assessing relevant potential safety vulnerability is essential to translation of brilliant science into an impactful therapy. Our scientists, our models and our depth of experience provide clients at the cutting edge, with the right resource to support them.